Document is current
Any future updates will be listed below
-
Authors
Yates, Kevin https://orcid.org/0000-0001-8509-8251
Berliner, Aaron J. https://orcid.org/0000-0002-4817-3926
Makrygiorgos, Georgios
Kaiyom, Farrah
McNulty, Matthew J. https://orcid.org/0000-0001-9025-102X
Khan, Imran
Kusuma, Paul
Kinlaw, Claire
Miron, Diogo
Legg, Charles https://orcid.org/0000-0003-4530-1774
Wilson, James
Bugbee, Bruce
Mesbah, Ali
Arkin, Adam P.
Nandi, Somen
McDonald, Karen A. https://orcid.org/0000-0002-5145-9968
-
Funding
Funding for this research was provided by:
National Aeronautics and Space Administration (NNX17AJ31G)
National Aeronautics and Space Administration (NNX17AJ31G)
National Aeronautics and Space Administration (NNX17AJ31G)
National Aeronautics and Space Administration (NNX17AJ31G)
National Aeronautics and Space Administration (NNX17AJ31G)
National Aeronautics and Space Administration (NNX17AJ31G)
National Aeronautics and Space Administration (NNX17AJ31G)
National Aeronautics and Space Administration (NNX17AJ31G)
National Aeronautics and Space Administration (NNX17AJ31G)
National Aeronautics and Space Administration (NNX17AJ31G)
National Aeronautics and Space Administration (NNX17AJ31G)
National Aeronautics and Space Administration (NNX17AJ31G)
- License Information
-
More Information
Article History
Received: 1 March 2024
Accepted: 27 August 2024
First Online: 28 September 2024
Competing interests
: The authors K.Y., A.J.B., G.M., F.K., M.J.M., I.K., P.K., A.M., A.P.A., S.N., and K.A.M. declare no competing interests. Authors C.K., D.M., C.L., and J.W. are employees of Zea Biosciences, a biologics platform company with a financial interest in identifying, producing, and growing high-potency drugs.
